Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Biologic-Naive Psoriatic Arthritis
NCT04115748Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (6 arms), sponsored by Gilead Sciences. Primary endpoint: American College of Rheumatology 20% Improvement Response at 16 weeks. Started Dec 2019; status: terminated.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04115748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115748.